Pharmacogenomics · 2025
Pharmacogenomic markers associated with drug-induced QT prolongation: a systematic review.
СтатьяСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bentestuen Marlene Schouby, Weis Christian Noe, Jeppesen Caroline Bækmann, Thiele Liv Swea, Thirstrup Janne Pia, Cordero-Solorzano Juan, Jensen Henrik Kjærulf, Starnawska Anna, Hauser Alexander Sebastian, Gasse Christiane
Аннотация
AIM: To systematically assess clinical studies involving patients undergoing drug therapy, comparing different genotypes to assess the relationship with changes in QT intervals, with no limitations on study design, setting, population, dosing regimens, or duration.
METHODS: This systematic review followed PRISMA guidelines and a pre-registered protocol. Clinical human studies on PGx markers of diQTP were identified, assessed using standardized tools, and categorized by design. Gene associations were classified as pharmacokinetic or pharmacodynamic. Identified genes underwent pathway enrichment analyses. Drugs were classified by third-level Anatomical Therapeutic Chemical (ATC) codes. Descriptive statistics were computed by study category and drug classes.
RESULTS: Of 4,493 reports, 84 studies were included, identifying 213 unique variants across 42 drug classes, of which 10% were replicated. KCNE1-Asp85Asn was the most consistent variant. Most findings (82%) were derived from candidate gene studies, suggesting bias toward known markers. The diQTP-associated genes were mainly linked to "cardiac conduction" and "muscle contraction" pathways (false discovery rate = 4.71 × 10-14). We also found an overlap between diQTP-associated genes and congenital long QT syndrome genes.
CONCLUSION: Key genes, drugs, and pathways were identified, but few consistent PGx markers emerged. Extensive, unbiased studies with diverse populations are crucial to advancing the field.
REGISTRATION: A protocol was pre-registered at PROSPERO under registration number CRD42022296097.
DATA DEPOSITION: Data sets generated by this review are available at figshare: DOI: 10.6084/m9.figshare.27959616.
METHODS: This systematic review followed PRISMA guidelines and a pre-registered protocol. Clinical human studies on PGx markers of diQTP were identified, assessed using standardized tools, and categorized by design. Gene associations were classified as pharmacokinetic or pharmacodynamic. Identified genes underwent pathway enrichment analyses. Drugs were classified by third-level Anatomical Therapeutic Chemical (ATC) codes. Descriptive statistics were computed by study category and drug classes.
RESULTS: Of 4,493 reports, 84 studies were included, identifying 213 unique variants across 42 drug classes, of which 10% were replicated. KCNE1-Asp85Asn was the most consistent variant. Most findings (82%) were derived from candidate gene studies, suggesting bias toward known markers. The diQTP-associated genes were mainly linked to "cardiac conduction" and "muscle contraction" pathways (false discovery rate = 4.71 × 10-14). We also found an overlap between diQTP-associated genes and congenital long QT syndrome genes.
CONCLUSION: Key genes, drugs, and pathways were identified, but few consistent PGx markers emerged. Extensive, unbiased studies with diverse populations are crucial to advancing the field.
REGISTRATION: A protocol was pre-registered at PROSPERO under registration number CRD42022296097.
DATA DEPOSITION: Data sets generated by this review are available at figshare: DOI: 10.6084/m9.figshare.27959616.